表紙
市場調查報告書
商品編碼
210366

全球分子細胞遺傳學市場

Molecular Cytogenetics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 485 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球分子細胞遺傳學市場相關調查,市場趨勢與各市場區隔概要,各地區趨勢,及市場與進入主要企業的簡介競爭趨勢相關資訊。

第1章 簡介,調查方法,產品定義

第2章 產業概要

  • 分子細胞遺傳學技術:簡介
  • 對細胞遺傳學技術有前途的未來預測
  • 生命科學的研究開發與醫療支出創造有利的環境
  • 已開發國家:主要的收益貢獻國
  • 發展中國家的急速成長預測
  • 經濟方案促進市場發展的擴大

第3章 市場趨勢,促進要素

  • 實驗室處理的分子生物學的重要性
  • 分子生物學技術的進步
  • 陣列為基礎的技術:最大且最快成長的市場區隔
  • 從FISH轉移到陣列技術
  • 次世代定序摸索細胞遺傳學流程的作用
  • 對癌症的預後也有大幅貢獻
  • FISH技術的多樣應用 其他

第4章 技術概要

  • 細胞遺傳學的序論
  • 分子生物學的基本用語和定義
  • 分子細胞遺傳學:定義和範圍
  • 分子細胞遺傳學的應用
  • 技術趨勢
  • 微陣列技術的探求 其他

第5章 競爭環境

  • 主要企業
  • 產品上市
  • 近幾年的產業活動

第6章 全球市場預測

第7章 各地區市場預測

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 南美

第8章 企業簡介

目錄
Product Code: MCP-6759

Abstract:

Global Molecular Cytogenetics Market to Reach $2.5 Billion by 2026

Molecular Cytogenetics involves all aspects of chromosome biology, such as structural and functional organization of the chromosome and nucleus, chromosomal variation and abnormalities, and the applications of chromosome biology in medicine and tumor genetics. Cytogenetics plays an important role in identification of genetic predisposition to disease and also a person`s reaction to a certain drug. Molecular biology techniques evolved from simple tools such as In situ Hybridization (ISH), which detects the presence, quantity, and location of DNA/RNA sequences in cells and tissues, by using a labeled sequence fragment called a "probe". These screening tests analyze complicated genomic interactions and help to determine the progress of a disease. Amid the COVID-19 crisis, the global market for Molecular Cytogenetics estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2026, growing at a CAGR of 7.7% over the analysis period. Consumables, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$1.6 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $746.7 Million in 2021, While China is Forecast to Reach $159.7 Million by 2026

The Molecular Cytogenetics market in the U.S. is estimated at US$746.7 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$159.7 Million by the year 2026 trailing a CAGR of 8.9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Growth in these markets is driven by increasing incidence of cancer and genetic abnormalities, need for rapid disease diagnosis through genetic techniques, as well as higher funding (both public and private) leading to introduction of highly advanced cytogenetic techniques and their broadening applications are some of the key factors poised to contribute to future growth. Significant rise in target patient population across the world, and rising preference for CGH in clinical diagnosis, is expected to drive the market further, providing players with lucrative opportunities. Growing awareness levels of genetic disorders and expanding pool of research laboratories specializing in molecular biology techniques, would be beneficial for cytogenetics solutions. Rise in incidence of cancer and the subsequent demand for personalized medicine, is likely to enhance market prospects in a major way.

Software & Services Segment to Reach $451.8 Million by 2026

In the global Software & Services segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$231.2 Million in the year 2020 will reach a projected size of US$404.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$24.1 Million by the year 2026, while Latin America will expand at a 9.2% CAGR through the analysis period.

Select Competitors (Total 44 Featured) -

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • Applied Spectral Imaging
  • Bio-Rad Laboratories Inc.
  • Cytognomix Inc.
  • CytoTest Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Leica Biosystems Nussloch GmbH
  • Oxford Gene Technology
  • PerkinElmer Inc.
  • SciGene Corporation
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of COVID-19 and a Looming Global Recession
    • EXHIBIT 1: COVID-19 Leaves the World in Shambles & Industries and Markets Upended: World Economic Growth Projections (Real GDP, Annual % Change) for 2019E to 2022F
    • Challenges and Opportunities for Clinical Diagnostics amid the Pandemic
    • French Research Team Develops CoronaFISH
    • Immuno RNA Fluorescence ISH for Visualization of COVID-19 Causing SARS-CoV-2
    • Molecular Cytogenetics Technologies: An Introductory Prelude
    • Future Prospects Remain Favorable for Cytogenetics Technologies
    • Uptrend in Life Sciences R&D and Healthcare Spending Creates Fertile Environment
    • EXHIBIT 2: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Northbound Trajectory in Med Tech Sector to Generate Parallel Opportunities
    • Developed Regions: Key Revenue Contributors
    • EXHIBIT 4: Developed Regions Account for Lion's Share of World Molecular Cytogenetics Technologies Market: Percentage Breakdown of Revenues for Developed and Developing Regions (2020E & 2027P)
    • Fast Paced Growth Projected in Developing Regions
    • EXHIBIT 5: Global Market for Molecular Cytogenetics Technologies - Geographic Regions Ranked by % CAGR (Revenues) for 2020-2027: China, Asia-Pacific, Latin America, USA, Middle East, Africa, Canada, Europe, and Japan
    • Competitive Scenario
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Critical Importance of Molecular Biology in Laboratory Processes: Cornerstone for Present & Future Growth
    • Advanced Molecular Biology Techniques Broaden the Scope of Cytogenetics Technologies
    • Comparative Genome Hybridization (CGH): Largest & Fastest Growing Market Segment
    • Rising Adoption of Array Based CGH to Spur Overall Demand
    • EXHIBIT 6: Array-based Technologies Continue to Cannibalize Sales from FISH Technology: Percentage (%) Share of Array-Based Solutions in World Cytogenetics Technologies Market (2018 & 2022)
    • aCGH Simplifies Diagnosis of Chromosomal Anomalies
    • Clinical Pathological Testing: A Growing Vertical for aCGH
    • Impact of Rising Emphasis on R&D on Microarray Technology
    • Leveraging Established Use Case, FISH Technology Continues to Find Favor
    • Next Generation Sequencing Seeks Role in Cytogenetics Processes
    • Molecular Cytogenetics Greatly Benefit Cancer Prognosis
    • EXHIBIT 7: Breakdown of Total Number of Cancer Cases by Region: 2020
    • EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Type: 2020
    • EXHIBIT 9: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Cancer Care Made Easier with Highly-Multiplexed FISH
    • Diverse Applications of FISH Technology in Oncology
    • Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
    • Increasing Significance of Cytogenetic Analysis in Genetic Disease Diagnosis
    • Uptrend in Genetic Disease Testing Augments Prospects
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Top Ten Genetic Diseases Worldwide
    • Proven Efficacy in Nucleic Acid Diagnostics Favors Market Growth
    • Expanding Role of Molecular Cytogenetics in Personalized Medicine
    • EXHIBIT 10: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • EXHIBIT 11: World Personalized Medicine Market by Region/Country (2021): Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
    • EXHIBIT 12: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • Companion Diagnostics Lead the Way to Personalized Medicine
    • Digitalization, Automation and AI Trends Set to Shape Future Growth
    • Lab Automation Speeds Up
    • EXHIBIT 13: World Laboratory Automation Market in US$ Billion for Years 2018, 2020, 2022, 2024 & 2026
    • Laboratory 4.0 Set to Transform Molecular Cytogenetics Landscape
    • Laboratory Information Systems Gain Traction
    • Artificial Intelligence : The Future of LIS
    • Biotech Research Spending Patterns Steer Momentum
    • Technology Advancements & Improvements Bolster Growth
    • Ageing Demographics to Drive Demand
    • EXHIBIT 14: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 15: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • EXHIBIT 16: Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
    • Technology Overview
    • A Preface to Cytogenetics
    • Basic Terms and Definitions in Molecular Biology
    • An Overview of Select Chromosomal Anomalies
    • Insight into Molecular Cytogenetics Techniques
    • Fluorescence in situ Hybridization (FISH)
    • Comparative Genomic Hybridization (CGH)
    • Advent of Microarray Technology
    • Microarrays in Comparative Genomic Hybridization
    • Principle Underlying aCGH
    • Low Resolution and High Resolution aCGH
    • A Review of Molecular Biology Techniques in Cytogenetics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for CGH by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for FISH by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Karyotyping by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Clinical & Research Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: World 15-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 49: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 50: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • The United States: Prime Market for Cytogenetics Technologies
    • CGH Technologies Witness Higher Adoption
    • Established Role Sustains Momentum in FISH Technology
    • Ageing Population and Growing Incidence of Cancer & Lifestyle Diseases - Opportunity Indicators
    • EXHIBIT 17: US Elderly Population: Expected Growth Rates Over the Years 2005-2025
    • EXHIBIT 18: Leading Sites of New Cancer Cases in Males: 2020
    • EXHIBIT 19: Leading Sites of New Cancer Cases in Females: 2020
    • Emphasis on Personalized Medicine & Companion Diagnostics Widens Scope
    • EXHIBIT 20: US Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018 and 2022
    • EXHIBIT 21: US Companion Diagnostics (CDx) Market: Breakdown of Revenues (in US$ Million) for 2014, 2018 and 2022
    • Growing Focus on Genetic Testing Widens the Business Case
    • Emphasis on Early Diagnosis & Need to Reduce Healthcare Costs Augment Demand
    • Market Analytics
    • TABLE 52: USA Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 58: USA Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: USA Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: USA 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 61: USA Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: USA Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: USA 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • An Overview
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • EXHIBIT 22: Number of New Cancer Cases in Canada: 2019
    • Market Analytics
    • TABLE 64: Canada Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 67: Canada Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Canada Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Canada 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 70: Canada Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Canada Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Canada 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 73: Canada Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Canada Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Canada 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • Japan Offers Robust Opportunities
    • EXHIBIT 23: Japanese Elderly (65+ Years) Population: 2000-2020
    • EXHIBIT 24: Breakdown of Population by Age Group in Japan: 2010, 2020, and 2025
    • Market Analytics
    • TABLE 76: Japan Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Japan Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Japan 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 79: Japan Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Japan Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Japan 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 82: Japan Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Japan Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Japan 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 85: Japan Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Japan Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Japan 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • Market Overview
    • Market Analytics
    • TABLE 88: China Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: China Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: China 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 91: China Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: China Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: China 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 94: China Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: China Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: China 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 97: China Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: China Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: China 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • A Mature yet Growing Market
    • EXHIBIT 25: Number of New Cancer Cases in Europe: 2012, 2018, and 2025
    • EXHIBIT 26: Distribution of New Cancer Cases by Type in Europe: 2018
    • Market Analytics
    • TABLE 100: Europe Current & Future Analysis for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 103: Europe Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Europe Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Europe 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 106: Europe Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Europe 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 109: Europe Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Europe 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 112: Europe Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Europe 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 115: France Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: France Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: France 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 118: France Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: France Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: France 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 121: France Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: France Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: France 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 124: France Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: France Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: France 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 127: Germany Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Germany Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Germany 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 130: Germany Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Germany Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Germany 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 133: Germany Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Germany Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Germany 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 136: Germany Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Germany Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Germany 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 139: Italy Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Italy Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Italy 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 142: Italy Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Italy Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Italy 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 145: Italy Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Italy Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Italy 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 148: Italy Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Italy Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Italy 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • Market Overview
    • Market Analytics
    • TABLE 151: UK Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: UK Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: UK 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 154: UK Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: UK Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: UK 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 157: UK Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: UK Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: UK 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 160: UK Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: UK Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: UK 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 163: Spain Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Spain Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Spain 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 166: Spain Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Spain Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Spain 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 169: Spain Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Spain Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Spain 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 172: Spain Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Spain Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Spain 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 175: Russia Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Russia Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Russia 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 178: Russia Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Russia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Russia 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 181: Russia Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Russia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Russia 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 184: Russia Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Russia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Russia 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 187: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Europe Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • Market Overview
    • Factors Driving Demand for Laboratory Technologies in Asia-Pacific
    • Market Analytics
    • TABLE 199: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 200: Asia-Pacific Historic Review for Molecular Cytogenetics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 202: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Asia-Pacific Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 205: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Asia-Pacific Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 208: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Asia-Pacific Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 211: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Asia-Pacific Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 214: Australia Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Australia Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Australia 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 217: Australia Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Australia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Australia 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 220: Australia Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Australia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Australia 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 223: Australia Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Australia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Australia 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • INDIA
    • Indian Microarray Market
    • Market Analytics
    • TABLE 226: India Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: India Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: India 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 229: India Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: India Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: India 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 232: India Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: India Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: India 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 235: India Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: India Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: India 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 238: South Korea Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: South Korea Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: South Korea 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 241: South Korea Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: South Korea Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: South Korea 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 244: South Korea Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: South Korea Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: South Korea 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 247: South Korea Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: South Korea Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: South Korea 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 250: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 256: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 259: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 262: Latin America Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 263: Latin America Historic Review for Molecular Cytogenetics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Latin America 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 265: Latin America Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Latin America Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Latin America 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 268: Latin America Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Latin America Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Latin America 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 271: Latin America Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Latin America Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Latin America 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 274: Latin America Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Latin America Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Latin America 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 277: Argentina Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Argentina Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Argentina 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 280: Argentina Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Argentina Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: Argentina 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 283: Argentina Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Argentina Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: Argentina 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 286: Argentina Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Argentina Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: Argentina 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 289: Brazil Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Brazil Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Brazil 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 292: Brazil Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Brazil Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Brazil 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 295: Brazil Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Brazil Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Brazil 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 298: Brazil Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Brazil Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Brazil 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 301: Mexico Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Mexico Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Mexico 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 304: Mexico Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Mexico Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Mexico 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 307: Mexico Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Mexico Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 309: Mexico 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 310: Mexico Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Mexico Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 312: Mexico 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 313: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 314: Rest of Latin America Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 315: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 316: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Rest of Latin America Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 318: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 319: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 320: Rest of Latin America Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 321: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 322: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 323: Rest of Latin America Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 324: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 325: Middle East Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 326: Middle East Historic Review for Molecular Cytogenetics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 327: Middle East 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 328: Middle East Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 329: Middle East Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 330: Middle East 15-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 331: Middle East Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 332: Middle East Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 333: Middle East 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 334: Middle East Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 335: Middle East Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 336: Middle East 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 337: Middle East Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 338: Middle East Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 339: Middle East 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 20